Breast Density
Breast density refers to the relative proportion of fibroglandular tissue (glands and connective tissue) compared to fatty tissue within the breast, as observed on a mammogram. It is a common characteristic that varies significantly among women and is influenced by a complex interplay of genetic, hormonal, and environmental factors.
Biological Basis
The human breast is composed of various tissues, primarily glandular tissue (which produces milk), fibrous connective tissue (which supports the breast), and fatty tissue. Breast density is a qualitative assessment reflecting the amount of fibroglandular tissue relative to fatty tissue. A higher proportion of fibroglandular tissue results in denser breasts. This tissue composition is dynamic, changing throughout a woman's life due to factors such as age, menopausal status, parity, hormone therapy, and genetics. Genetic factors are known to play a substantial role in determining an individual's breast density, with heritability estimates suggesting a strong inherited component.
Clinical Relevance
Breast density is a well-established independent risk factor for breast cancer. Women with dense breasts have a higher risk of developing breast cancer compared to women with fatty breasts. Furthermore, dense breast tissue can obscure tumors on mammograms, making it more challenging for radiologists to detect cancers. Both cancerous lesions and dense tissue appear white on a mammogram, creating a "masking effect" that can delay diagnosis. This reduced mammographic sensitivity in dense breasts often necessitates the consideration of supplemental screening methods.
Social Importance
The understanding of breast density has significant implications for public health and personalized medicine. As a key risk factor for breast cancer and a determinant of mammographic efficacy, breast density has led to the development of personalized screening guidelines. Many regions have implemented breast density notification laws, informing women about their breast density status and the associated implications for breast cancer risk and screening. This awareness empowers women and healthcare providers to make informed decisions about screening strategies, potentially including additional imaging modalities like ultrasound or MRI for women with very dense breasts, to improve early detection and outcomes.
Methodological and Statistical Constraints
Genetic association studies for complex traits like breast density are subject to several methodological and statistical limitations. A primary challenge is that current studies are often constrained by sample size, which limits the statistical power to detect genetic variants with small effect sizes, especially those explaining only a minor fraction of the trait's variance. [1] This underpowering means that real genetic effects specific to certain demographic subgroups (e.g., by sex or age) or those stemming from rare alleles may remain undetected, thus providing an incomplete picture of breast density's genetic architecture . [1], [2] Consequently, the ability to consistently replicate initial findings is hampered, particularly when the identified effect sizes are small, which can lead to inconsistencies across independent research efforts . [3], [4]
Furthermore, the "winner's curse" phenomenon can inflate the estimated effect sizes in the initial discovery phases of genetic studies, making subsequent replication attempts challenging and potentially leading to a lack of concordance in reported associations . [5], [6], [7] Differences in genotyping platforms, SNP filtering algorithms, and the specific statistical methods employed can also contribute to replication gaps, even among studies of comparable size . [1], [8], [9] While stringent genome-wide significance thresholds are applied to mitigate false positives arising from multiple hypothesis testing, these conservative criteria may inadvertently result in missing true genetic associations that exert more modest effects on breast density . [1], [6], [7], [9]
Phenotypic Heterogeneity and Population Generalizability
The definition and assessment of complex traits, including breast density, can vary across different studies, potentially impacting the consistency and comparability of genetic findings. For example, in related traits like bone mineral density (BMD), different skeletal sites (e.g., spine versus femoral neck) are known to exhibit distinct genetic influences . [3], [7], [9] By analogy, variations in how breast density is quantified, such as through different imaging modalities, software algorithms, or definitions of dense tissue, could lead to heterogeneous genetic associations. Such phenotypic heterogeneity can obscure genuine genetic signals or contribute to inconsistent results, thereby complicating the comprehensive understanding of breast density genetics.
A significant limitation of many genetic association studies is their predominant inclusion of individuals of European ancestry. [5] This demographic bias means that allele frequencies, patterns of linkage disequilibrium, and the overall genetic architecture of breast density may differ substantially in other ancestral groups, limiting the direct applicability of findings to a global population . [3], [8] While methodologies like EIGENSTRAT are utilized to control for population stratification and minimize spurious associations within studies, the fundamental lack of diverse representation in cohorts restricts the generalizability of established genetic risk factors and impedes the development of equitable risk prediction models for breast density across varied populations . [3], [7], [9], [10], [11]
Complex Genetic Architecture and Environmental Influences
Current genetic association study designs are often underpowered to fully investigate the intricate interplay of gene-gene and gene-environment interactions, which are crucial for a complete understanding of traits like breast density . [1], [3] These complex interactions, along with the effects of rare alleles that are not typically captured by common SNP arrays, contribute significantly to the phenomenon of "missing heritability". [1] The inability to comprehensively account for these multifaceted genetic and environmental influences means that a substantial portion of the heritable variation in breast density remains unexplained, thereby hindering the development of exhaustive biological understandings and robust risk prediction models.
Furthermore, significant knowledge gaps persist regarding the precise functional consequences of identified genetic variants and their underlying biological mechanisms related to breast density. Many associated single nucleotide polymorphisms (SNPs) may serve as markers in linkage disequilibrium with the true functional variants, necessitating extensive follow-up research to pinpoint causal genes and pathways. [4] Additionally, the direct clinical impact of these genetic associations, such as their predictive value for breast cancer risk or their influence on the efficacy of screening methods, often requires dedicated investigation beyond the scope of initial genetic discovery studies. [1]
Variants
Genetic variations play a crucial role in influencing various biological processes, including those that contribute to breast tissue composition and density. Single nucleotide polymorphisms (SNPs) across the genome can impact gene expression, protein function, or regulatory pathways, thereby modulating an individual's susceptibility to complex traits like breast density, which itself is a strong risk factor for breast cancer. [12] Understanding these variants and their associated genes provides insight into the underlying biological mechanisms governing breast health. [2]
Variants such as *rs189070945* and *rs184752769* are located within the _CTNNA3_ (Catenin Alpha 3) gene, which encodes a protein vital for cell-cell adhesion by linking cadherin complexes to the actin cytoskeleton. Alterations in _CTNNA3_ can affect cell adhesion, tissue architecture, and cellular signaling pathways, all of which are important for maintaining normal breast tissue structure and may influence breast density. [5] Similarly, *rs191367039* in _ARHGAP10_ (Rho GTPase Activating Protein 10) is of interest, as _ARHGAP10_ regulates Rho GTPases, key molecular switches that control cell migration, adhesion, and proliferation—processes fundamental to breast tissue development and potential remodeling. [13] The variant *rs142447005* near _CYRIA_ (LINC01866), a long non-coding RNA, may also contribute to these cellular dynamics by influencing cytoskeletal organization or cell signaling pathways, thereby affecting cell shape and interactions within the mammary gland.
Other variants, including *rs184938993* in _HSD17B6_ (Hydroxysteroid 17-Beta Dehydrogenase 6), are relevant due to their roles in hormone metabolism. _HSD17B6_ is involved in the inactivation of androgens, and the balance of steroid hormones is a critical determinant of breast tissue proliferation and differentiation, directly impacting breast density. [12] The variant *rs139721819* is located in _UGDH-AS1_, an antisense long non-coding RNA associated with _UGDH_ (UDP-glucose 6-dehydrogenase), a gene involved in carbohydrate metabolism and extracellular matrix synthesis. Modulations in these metabolic and structural pathways can alter the composition and density of breast tissue. [14] Additionally, *rs6912620* in _TAAR8_ (Trace Amine Associated Receptor 8) may influence breast density through its role as a G-protein coupled receptor, potentially affecting cell growth or metabolic processes within breast tissue, although its precise ligands and physiological functions are still under investigation.
Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are crucial regulators of gene expression, and variants within their loci can have widespread effects. *rs143065709* associated with _BOD1L2_ - LINC02565 and *rs150208861* linked to _LINC02312_ - LINC01550 represent variations in long intergenic non-coding RNAs, which are known to participate in diverse regulatory mechanisms, including chromatin remodeling, transcription, and post-transcriptional processing. [2] Such regulatory changes can impact the development and maintenance of breast tissue, potentially contributing to variations in breast density. Furthermore, *rs73886707* in _MIRLET7BHG_, the host gene for _miR-let-7b_, is significant as _miR-let-7b_ is a well-established tumor suppressor microRNA that regulates cell proliferation, differentiation, and apoptosis. Alterations in its expression or function, potentially influenced by this variant, could modify cellular growth patterns in the breast and affect breast density. [5]
Finally, *rs113187843* in _SIL1_ (SIL1 Nucleotide Exchange Factor) highlights the importance of protein quality control in breast tissue. _SIL1_ functions as a nucleotide exchange factor for the _BiP_ chaperone, a critical component of the endoplasmic reticulum (ER) stress response pathway responsible for proper protein folding. Dysregulation of protein folding and ER stress can lead to cellular dysfunction, altered cell survival, and changes in tissue homeostasis, which are factors that can contribute to variations in breast tissue architecture and density. [13] These genetic variations collectively underscore the complex interplay of cellular adhesion, metabolism, hormonal regulation, gene expression, and protein quality control in shaping breast density.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs142447005 | CYRIA - LINC01866 | breast density |
| rs189070945 rs184752769 |
CTNNA3 | breast density |
| rs184938993 | HSD17B6 | breast density |
| rs139721819 | UGDH-AS1 | breast density |
| rs191367039 | ARHGAP10 | breast density |
| rs6912620 | TAAR8 | breast density |
| rs143065709 | BOD1L2 - LINC02565 | breast density |
| rs73886707 | MIRLET7BHG | breast density |
| rs150208861 | LINC02312 - LINC01550 | breast density |
| rs113187843 | SIL1 | breast density |
Biological Background of Breast Density
Breast density refers to the relative proportions of fibroglandular tissue (dense tissue) and fatty tissue within the breast, as observed on mammograms. Variations in breast density are influenced by a complex interplay of genetic, hormonal, and environmental factors, with significant implications for breast health, particularly as a risk factor for breast cancer. Understanding the biological mechanisms that govern breast tissue composition is crucial for comprehending this trait.
Hormonal and Growth Factor Regulation of Breast Tissue
The biological characteristics of breast tissue, which contribute to its density, are significantly influenced by systemic hormonal regulation. Pathways involving androgen and oestrogen metabolism are central, having been associated with the development of postmenopausal breast cancer, a condition often linked to altered breast tissue composition. [14] Specifically, the ESR1 gene, encoding the estrogen receptor alpha, shows polymorphisms that affect bone mineral density, suggesting a broader role for estrogen signaling in tissue architecture, including potentially breast tissue. [15] The enzyme aromatase, encoded by the CYP19A1 gene, is critical for estrogen synthesis, and its genetic variations also impact bone mineral density, further underscoring the systemic influence of estrogen production on tissue properties . [16], [17]
Beyond sex hormones, growth factors also play a crucial role in regulating cellular proliferation and tissue development, thereby influencing breast tissue characteristics. Insulin-like growth factor-I (IGF-I) has been studied for its relationships with bone mineral density, indicating its systemic importance in regulating tissue growth and maintenance. [9] Such growth factors, alongside hormonal signals, form a complex regulatory network that dictates the cellular functions and overall composition of breast tissue, contributing to variations in its density. These biomolecules act through specific receptors and signaling pathways to modulate cell growth, differentiation, and survival, ultimately shaping the macroscopic properties of the breast.
Genetic Determinants and Regulatory Mechanisms
Genetic mechanisms significantly contribute to the variability in breast tissue characteristics. Genome-wide association studies (GWAS) have identified numerous loci associated with breast cancer susceptibility, which are implicitly linked to the underlying biological factors that influence breast density, a known risk factor . [5], [6], [8], [13], [14] These include regions on chromosomes 1p11.2, 2q35, 3p, 5p12, 8q24, 10q23.13, 14q24.1, and 16q [14] as well as 6q22.33 [8] 19p13 [12] 3p24, and 17q23.2. [5] Specific single nucleotide polymorphisms (SNPs) within these regions, such as rs4784227 at 16q12.1, have demonstrated functional significance in vitro, suggesting they modulate gene expression or protein function that contributes to breast tissue properties. [18]
Regulatory elements and transcription factors play a key role in mediating these genetic effects. For instance, an allele change at rs2273061 in intron 3 has been shown to potentially create a binding site for the transcription factor c-Myc. [9] c-Myc is a known regulator of cell proliferation and growth, and its altered binding could influence gene expression patterns that determine cellular characteristics and, consequently, breast tissue composition. The interplay between genetic variants, their regulatory elements, and critical transcription factors establishes complex networks that dictate the cellular functions and developmental processes within the breast, contributing to individual differences in density.
Cellular Metabolism and Regulatory Pathways
Beyond direct hormonal and genetic influences, various molecular and cellular pathways are fundamental to maintaining breast tissue homeostasis and influencing its composition. Metabolic processes, such as mitochondrial fatty acid oxidation involving proteins like ECHDC1, and fatty acid synthase activity, are crucial for cell energy and membrane synthesis. [8] Disruptions in these pathways, for example, through fatty acid synthase inhibition, can trigger apoptosis, highlighting their importance in regulating cell survival and proliferation, which directly impacts tissue cellularity and density. [8] Similarly, the ubiquitin-proteasome pathway, which regulates protein degradation through enzymes like RNF146 and other E3 ubiquitin ligases, is vital for cellular protein turnover and signaling, with aberrations linked to disease states. [8]
Complex regulatory networks integrate these metabolic and protein turnover processes, influencing breast tissue characteristics. Pathways involved in the regulation of the actin cytoskeleton, glycan degradation, and alpha-linolenic acid metabolism have been suggestively associated with breast cancer development. [14] These pathways govern fundamental cellular functions such as cell shape, cell-cell interactions, and lipid metabolism, all of which contribute to the overall structure and density of breast tissue. The coordinated activity of critical enzymes and regulatory proteins within these pathways ensures proper cellular function and tissue organization, and their dysregulation can lead to altered tissue architecture and increased density.
Pathophysiological Implications and Disease Risk
Breast density is a significant pathophysiological factor, strongly linked to an increased risk of breast cancer. Genetic susceptibility loci identified through GWAS, such as those on 1p11.2, 2q35, 3p, 5p12, 8q24, 10q23.13, 14q24.1, 16q, 6q22.33, 19p13, 3p24, and 17q23.2, are associated with breast cancer risk and likely exert their influence, in part, by modulating the underlying biological characteristics that define breast density . [5], [6], [8], [12], [13], [14] These genetic variants can affect developmental processes and homeostatic regulation within the breast, leading to alterations in tissue composition that contribute to higher density and increased vulnerability to malignant transformation.
The biological mechanisms underlying these associations involve a complex interplay of genetic predisposition and cellular processes. For instance, a locus on 19p13 has been shown to modify breast cancer risk in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population, highlighting gene-environment interactions and distinct disease pathways. [12] Key tumor suppressor genes, such as p53, also play a critical role in preventing uncontrolled cell growth and maintaining genomic integrity, with their dysregulation contributing to cancer pathogenesis and potentially impacting the cellular characteristics of dense breast tissue. [8] Understanding these genetic and molecular underpinnings is crucial for elucidating how breast density contributes to disease mechanisms and for developing targeted prevention strategies.
Hormonal and Growth Factor Signaling Networks
Breast density is influenced by intricate hormonal and growth factor signaling pathways that regulate cellular proliferation, differentiation, and tissue remodeling. The estrogen receptor 1 (ESR1) gene and its associated polymorphisms are known to impact bone mineral density, and an ESR1 and MAPK3 network has been suggested for postmenopausal osteoporosis, indicating its broader role in tissue architecture. [19] Similarly, polymorphisms in the aromatase gene (CYP19A1), which is crucial for estrogen biosynthesis, affect areal bone mineral density by influencing cortical bone size. [17] Furthermore, alleles in the Fibroblast Growth Factor Receptor 2 (FGFR2) are associated with the risk of sporadic postmenopausal breast cancer, highlighting the role of FGFR2 signaling in tumorigenesis and the differential signal transduction of its alternatively spliced variants in human mammary epithelial cells. [20]
Beyond sex hormones, other signaling molecules like IL21R and parathyroid hormone (PTH) are implicated in variations of femoral neck bone mineral density, with genes for vitamin D receptor and osteocalcin also playing roles. [3] The TGF-beta receptor pathway also contributes to cellular regulation. [21] These diverse signaling cascades, involving receptor activation and intracellular signal transduction, converge to modulate cellular behavior, and their dysregulation can contribute to altered tissue characteristics, including breast density, and increased disease susceptibility.
Metabolic Reprogramming and Lipid Homeostasis
Metabolic pathways play a critical role in shaping breast tissue composition, particularly through lipid metabolism. Fatty acid synthase-dependent endogenous fatty acid synthetic activity is often abnormally elevated in aggressive breast carcinomas. [8] Conversely, inhibition of fatty acid oxidation can trigger apoptosis in breast cancer cell lines, an effect that is significantly amplified in TP53-silenced cells, suggesting a complex interplay between metabolic state and cell survival pathways. [8] The ECHDC1 gene, located at a breast cancer risk locus, is involved in mitochondrial fatty acid oxidation. [8]
Genetic studies have also pointed to suggestive associations for genes involved in alpha-linolenic acid metabolism, indicating a broader influence of various lipid metabolic processes on breast cancer susceptibility. [14] Additionally, pathways related to androgen and estrogen metabolism are marginally significant for postmenopausal breast cancer development. [14] These metabolic alterations, including dyslipidemia and variations in cholesterol and triglyceride levels, represent crucial mechanisms influencing cellular energy, biosynthesis, and catabolism, ultimately affecting tissue characteristics. [22]
Ubiquitin-Proteasome System and Gene Regulation
Regulatory mechanisms, particularly those governing gene expression and protein stability, are fundamental to maintaining normal cellular function and tissue homeostasis. The ubiquitin-proteasome system is a critical pathway that regulates a myriad of cellular processes, including the cell cycle, apoptosis, transcription, protein trafficking, signaling, DNA replication and repair, and angiogenesis. [8] Defects within this pathway are well-documented in breast cancer, suggesting its direct involvement in disease progression and potentially in altered breast tissue characteristics. [23]
For instance, RNF146 (also known as dactylidin), located within a breast cancer risk locus, encodes a protein with a C3HC4 RING finger domain and likely functions as an E3 ubiquitin protein ligase. [8] This highlights how specific genetic variants can impact post-translational regulation and protein turnover, influencing critical cellular decisions. At the transcriptional level, gene regulation involves complex processes like promoter competition and the control of adjacent gene transcription by intergenic transcripts, as revealed by high-resolution transcriptional mapping. [24] These layers of regulation ensure precise control over protein abundance and activity, and their dysregulation can lead to emergent properties at the tissue level, such as increased breast density.
Integrated Cellular Responses and Disease Susceptibility
The pathogenesis of altered breast density and breast cancer susceptibility involves the systems-level integration of multiple pathways, often characterized by intricate crosstalk and hierarchical regulation. Genetic studies have identified several loci associated with breast cancer susceptibility, including regions on 1p11.2, 2q35, 3p, 5p12, 8q24, 10q23.13, 14q24.1, and 16q. [14] Some of these regions contain genes involved in the regulation of the actin cytoskeleton, glycan degradation, alpha-linolenic acid metabolism, circadian rhythm, hematopoietic cell lineage, and drug metabolism, suggesting broad network interactions. [14]
The interaction between metabolic and regulatory pathways is exemplified by the drastic increase in apoptosis observed when TP53-silenced breast cancer cells undergo inhibition of fatty acid metabolism, demonstrating a critical compensatory mechanism. [8] Furthermore, specific genetic variants, such as those in LRP5 and JAG1, have been linked to bone mineral density variations and osteoporotic fractures, illustrating how common genetic factors can influence tissue characteristics across different systems. [19] The PBX1 gene also shows functional and potential genetic association with bone mineral density. [9] This systems-level integration of genetic predispositions and pathway dysregulation ultimately contributes to the emergent properties observed in breast density and its associated disease risks.
Frequently Asked Questions About Breast Density
These questions address the most important and specific aspects of breast density based on current genetic research.
1. My mom has dense breasts; will I have them too?
Yes, there's a strong likelihood. Breast density has a substantial inherited component, meaning genetics play a significant role in determining it. If your mother has dense breasts, you have an increased chance of having dense breasts yourself, although other factors also contribute.
2. My sister has fatty breasts, but mine are dense. Why?
Even with a strong genetic link, breast density is influenced by many factors beyond just inherited genes. Differences in age, menopausal status, whether you've had children, or hormone therapy can all lead to variations in breast density, even between close family members.
3. Does having kids affect my breast density risk?
Yes, having children, referred to as parity, is one of the factors known to influence breast density. The hormonal changes associated with pregnancy and childbirth contribute to the dynamic composition of breast tissue throughout a woman's life, interacting with her genetic predisposition.
4. Can I change my breast density with diet or exercise?
While genetics significantly determine your inherent breast density, it's also influenced by a complex interplay of hormonal and environmental factors. Though specific dietary or exercise impacts on density aren't detailed, a healthy lifestyle generally supports overall breast health and can interact with your genetic makeup.
5. If my breasts are dense, does that mean I'll definitely get cancer?
No, having dense breasts means you have a higher risk of developing breast cancer compared to women with fatty breasts, but it doesn't guarantee you'll get it. It's an independent risk factor, and many women with dense breasts never develop cancer.
6. Why is it harder for doctors to see cancer in my dense breasts?
Both dense breast tissue and cancerous lesions appear white on a mammogram. This creates a "masking effect," making it challenging for radiologists to distinguish tumors from the dense tissue. This reduced mammographic sensitivity is why supplemental screening methods are often considered.
7. I'm not European; does my background affect my density risk?
Yes, it can. Many genetic studies on breast density have predominantly included individuals of European ancestry. This means that the genetic risk factors and overall genetic architecture of breast density may differ in other ancestral groups, limiting the direct applicability of findings and potentially affecting risk assessment for you.
8. Does hormone therapy affect my breast density?
Yes, hormone therapy is a known factor that can influence breast density. Alongside your genetic predisposition, hormonal changes, including those from hormone therapy, can alter the proportion of glandular and fibrous tissue in your breasts over time.
9. Why do some women naturally have denser breasts than others?
The natural variation in breast density among women is largely due to a complex interplay of genetic, hormonal, and environmental factors. Genetics play a substantial role, meaning some women are simply predisposed to having a higher proportion of fibroglandular tissue from birth.
10. Should I get extra screening if my breasts are dense?
Yes, it's often recommended. Because dense breast tissue can obscure tumors on mammograms, healthcare providers frequently advise considering supplemental screening methods like ultrasound or MRI for women with very dense breasts. This personalized approach aims to improve the chances of early cancer detection.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Rivadeneira, F. et al. "Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies." Nat Genet, 2009.
[2] Murabito JM. "A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study." BMC Med Genet. 2007.
[3] Guo, Y. et al. "IL21R and PTH may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study." J Bone Miner Res, 2009.
[4] Hunter, D. J. et al. "A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer." Nat Genet, 2007.
[5] Ahmed S et al. "Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2." Nat Genet. 2009.
[6] Turnbull, C. et al. "Genome-wide association study identifies five new breast cancer susceptibility loci." Nat Genet, 2010.
[7] Xiong, D. H. et al. "Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups." Am J Hum Genet, 2009.
[8] Gold, B. et al. "Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33." Proc Natl Acad Sci U S A, 2008.
[9] Kung, A. W. Y. et al. "Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies." Am J Hum Genet, 2010.
[10] Thomas, G. et al. "A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)." Nat Genet, 2009.
[11] Smith, E. N. et al. "Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study." PLoS Genet, 2010.
[12] Antoniou AC et al. "A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population." Nat Genet. 2010.
[13] Easton DF et al. "Genome-wide association study identifies novel breast cancer susceptibility loci." Nature. 2007.
[14] Li J et al. "A combined analysis of genome-wide association studies in breast cancer." Breast Cancer Res Treat. 2011.
[15] Styrkarsdottir, U., et al. "ESR1 gene polymorphisms on osteoporosis outcomes." JAMA, vol. 292, no. 17, 2004, pp. 2105-2114.
[16] Lorentzon, M., et al. "Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study." Journal of Bone and Mineral Research, vol. 21, no. 2, 2006, pp. 332-339.
[17] Enjuanes, A., et al. "A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women." Bone, vol. 38, no. 5, 2006, pp. 738-743.
[18] Long, J., et al. "Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium." PLoS Genetics, vol. 6, no. 6, 2010, e1001002.
[19] Kiel, D.P., et al. "Genome-wide association with bone mass and geometry in the Framingham Heart Study." BMC Med Genet, vol. 7, 2006, p. 86.
[20] Grose, R., Dickson, C. "Fibroblast growth factor signaling in tumorigenesis." Cytokine Growth Factor Rev, vol. 16, no. 2, 2005, pp. 179–186.
[21] Lebrin, F., Deckers, M., Bertolino, P., Ten Dijke, P. "TGF-beta receptor function in the endothelium." Cardiovasc Res, vol. 65, no. 3, 2005, pp. 599–608.
[22] Kathiresan, S., et al. "Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans." Nat Genet, vol. 40, no. 2, 2008, pp. 189–197.
[23] Chen, C., Seth, AK., Aplin, AE. "Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer." Mol Cancer Res, vol. 4, no. 10, 2006, pp. 695–707.
[24] Cheng, J., et al. "Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution." Science, vol. 308, no. 5725, 2005, pp. 1149–1154.